- Ongoing, recruitingTherapeutic use (Phase IV)
Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy
This study looks at treating an irregular heartbeat called atrial fibrillation (AF) early in people with a heart condition called hypertrophic cardiomyopathy (HCM). It's trying to find out if early treatment of AF helps prevent serious health issues like stroke or further heart problems.
For: Hypertrophic cardiomyopathy (HCM) is the most common genetically determined disease of the heart · characterized by a varied picture and clinical course. The first comprehensive clinical description of the disease comes from the 1960s. Currently · the disease is diagnosed on the basis of a phenotypic picture showing left ventricular hypertrophyPoland - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A randomized, open-label, single dose, cross-over bioavailability study evaluating the drug-drug interaction between Tritace 10, 10 mg, tablets and Tertensif SR 1.5 mg prolonged-release film-coated tablets when co-administered versus the administration of each product alone in two cohorts of healthy volunteers under fasting conditions. Sponsor's Study No.: RAM-IND-DDI-05-23
This study looks at how two common blood pressure medicines, Tritace 10 and Tertensif SR, act in the body when taken together compared to taking them alone. It's for healthy volunteers to see if one medicine changes how the other works.
For: NA - study in healthy subjectsCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adenoassociated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.
This study looks at a new gene therapy called Pariglasgene brecaparvovec for people with a rare liver condition called GSDIa. It aims to see if this new treatment can help reduce the amount of cornstarch they need to eat daily to keep their blood sugar stable.
For: Glycogen Storage Disease Type Ia (GSDIa)Denmark · Netherlands · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A parallel-group treatment, phase 2a, double-blind, placebo-controlled 2-arm study to show improvement of physical function in SF-36 (SF-36-PF) in participants treated with Vericiguat compared to placebo tablets participants with post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of ME/CFS criteria - VERI-LONG
This study looks at a new medicine called Vericiguat for people with ongoing symptoms after COVID-19. It aims to see if Vericiguat can improve physical activity and reduce fatigue compared to a dummy pill.
For: Post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of myalgic encephalomyelitis/chronic fatique syndrome (ME/CFS) criteriaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
This study looks at a new medicine called RTA 408 (also known as Skyclarys) for people with Friedreich's ataxia. It aims to see if the medicine is safe, how well it works to improve symptoms, and how it affects the body.
For: Friedreich's ataxiaAustria · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Evaluation of the efficacy of topical treatment with budesonide in children with Crohn's disease located in the esophagus and/or stomach and/or duodenum - BETHESDa
This study, called BETHESDa, is looking into how well a medicine called budesonide works for children with Crohn's disease that affects their food pipe, stomach, or the first part of their small bowel. They're checking if it can make visible signs of the disease disappear.
For: Crohn's diseasePoland